NCT00562666

Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells

Immunotherapy of Hepatocellular Carcinoma by Hepatic Intra Arterial Injection of Autologous Gamma-delta T Lymphocytes: A Phase I Study

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Rennes University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

For most patients with hepatocellular carcinoma, surgery or other curative procedures are not possible and only palliative measures could be applied (chemoembolization, targeted drugs, best supportive cares, etc). In the ICAR study, increasing doses of a cell therapy product will be evaluated in patients in a palliative setting. All patients will have one hepatic intra-arterial injection of immunological cells (gamma-delta T lymphocytes) and will be evaluated for safety.

Conditions

• Hepatocellular Carcinoma

Interventions

Type	Name	Description
OTHER	T gamma delta lymphocytes	Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes

Timeline

• Start date: 2008-02-01
• Primary completion: 2009-01-01
• Completion: 2009-01-01
• First posted: 2007-11-22
• Last updated: 2012-06-22

Locations

3 sites across 1 country: France